

News Releases

All Years

Search

Go

[Advanced Search](#)

MAR 12, 2021

Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist

FEB 1, 2021

Inhibrx Announces Participation in Upcoming Investor Conference

JAN 13, 2021

Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients

JAN 5, 2021

Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist

NOV 13, 2020

Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford

NOV 11, 2020

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

NOV 5, 2020

Inhibrx Announces Participation in Upcoming Investor and Scientific Conferences

AUG 21, 2020

Inhibrx Announces Closing of Initial Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

AUG 18, 2020

Inhibrx Announces Pricing of Initial Public Offering of Common Stock

JAN 8, 2020

Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-106, a Novel Hexavalent Agonist of OX40

Show per
page

«	1	2	3	4	5	6	7	8	»
---	-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	---	-------------------	---



<https://inhibrxbiosciences.investorroom.com/news-releases?l=10&o=60>